| (Values in U.S. Thousands) | Dec, 2022 | Dec, 2021 | Dec, 2020 | Dec, 2019 | Dec, 2018 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -4,370 | -33,780 | -25,410 | -17,380 | -26,960 |
| Net Income Growth | +87.06% | -32.94% | -46.20% | +35.53% | -103.63% |
Neu Base Therapeutics Inc (NBSE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
NeuBase Therapeutics Inc. is a biotechnology company. It is engaged in developing antisense therapies to address genetic diseases. The company's proprietary platform includes PATrOL(TM). NeuBase Therapeutics Inc., formerly known as Ohr Pharmaceutical Inc., is based in Pittsburgh, United States.
Fiscal Year End Date: 09/30